Loading...
Radient Technologies Inc.
RDDTF•PNK
Healthcare
Drug Manufacturers - Specialty & Generic
$0.00
$0.00(0.00%)

The company's financials show resilient growth, with revenue advancing from $569414.00 in Q1 2023 to $0.00 in Q4 2023. Gross profit remained healthy with margins at N/A in Q4 2023 compared to 1% in Q1 2023. Operating income hit $0.00 last quarter, sustaining a consistent N/A margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $0.00. Net income rose to $0.00, while earnings per share reached $0.00. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan